FindTrial
Sign In

Immunologic effect of zinc supplementation in HIV infected children receiving highly active antiretroviral therapy: A randomized, double blind placebo controlled trial.

Immunologic effect of zinc supplementation in HIV infected children receiving highly active antiretroviral therapy: A randomized, double blind placebo controlled trial.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2009/091/000971
Enrollment
50
Registered
2010-03-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- HIV

Interventions

Intervention1: Zinc: 20 mg/ day for 6 months Control Intervention1: Placebo: -

Sponsors

Indian Council of Medical Research New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: HIV infected children older than 6 months in whom initiation of antiretroviral therapy is indicated as per current guidelines (NACO).

Exclusion criteria

Exclusion criteria: 1. Children receiving zinc supplementation at time of screening for enrollment. 2. Children with clinical evidence of zinc deficiency. 3. Sick children with concurrent other infections, including pneumonia, diarrhea, TB.

Design outcomes

Primary

MeasureTime frame
CD4% valueTimepoint: 12 weeks and 24 weeks—

Secondary

MeasureTime frame
Viral loadTimepoint: 12 weeks and 24 weeks—

Countries

India

Contacts

Public ContactDr Rakesh Lodha
rakesh_lodha@hotmail.com011-26593621

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026